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ABSTRACT: This session focused on three topics related to clin-
ical development of novel anticancer therapies: (1) moving clini-
cal testing of new agents in early-stage, (2) strategies for clinical
evaluation of combinations between novel/molecularly targeted
agents, and (3) clinical development paradigm for vaccine related
biological therapeutics.
Monotherapy with molecularly targeted agents has up to now
only offered little clinical benefit in most solid tumours where the
molecular pathology has not been linked to a single genetic defect
or target. While the importance of combining targeted agents is
well recognized, clinical development of novel combination stud-
ies can be challenging, and requires careful considerations of the
regulatory, intellectual property as well as scientific issues.
Traditional design of clinical trials must be adapted to test the
clinical utility of new targeted agents in different settings and to
allow for translational research.
Cancer vaccines present unique developmental challenges.
Some potential solutions exist, but they are not widely known
nor is there any consensus about their use. A Cancer Vaccine Con-
sortium (CVC) was established with the goal to use collective
knowledge in the field to synthesize a flexible and applicable par-
adigm, reach a consensus on practical recommendations to
improve cancer vaccine development, and offer an accepted,
practical approach to cancer vaccine development.
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As anti-cancer drug discovery has shifted to a rational, molec-
ularly targeted approach, traditional clinical trial design must be
adapted to test the clinical utility of these new agents.1 Tradi-
tional cytotoxic drugs, which evolved from the concept that can-
cer could be cured by eradicating all cancer cells in the body, have
diverse mechanisms of action, but mostly target DNA. Their phar-
macological effects are non-selective and irreversible, affecting
all cells undergoing replication, normal and neoplastic. Dosing
is usually in cyclical pulses administered at the maximum toler-
ated dose (MTD), which results in substantial toxicity in many
patients. Phase I studies aim to establish the MTD, and phase II
studies assess response based on tumour shrinkage, usually mea-
sured by imaging techniques.
In contrast, target-based therapies are selected on the basis of
their mechanism of action and usually target a specific protein
that is involved in malignant transformation. The interaction
with their target (receptor or ligand) can be described by classical
drug–receptor theory. Pharmacological effects are generally
reversible. Dosing can be continuous at a tolerable dose. Phase I
studies use biological and pharmacokinetic endpoints to estimate
the optimal dose for inhibition of the target. Response assess-
ments in phase II is based on prevention of further tumour
growth, rather than tumour shrinkage. For many molecularly tar-
geted agents, phase I is relatively uninformative, the heteroge-
neous patient population often has late-stage disease with
limited organ reserves and co-morbidities. Toxicities are uncom-
mon, and the maximum therapeutic effect is usually achieved
well below MTD. The goal is to estimate the optimal biological
dose (OBD), gauge the interaction between the anticancer agent
and its target, and to rule out serious dose-related toxicities. For
phase II development, the goal is to assess the probability that
the product will have a positive benefit-risk ratio in phase III. This
assessment is made by focusing on important pathways and ‘fol-
lowing the biology’. Assessments often include multiple tumour
types and involve monitoring of biomarkers and surrogates of
patient benefit. Also in phase II, the frequency of safety events
is estimated.
Phase III development of targeted agents is similar to that for
cytotoxic agents; that is, it involves measuring clinical benefit
against a known standard of care (active comparator) in random-
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ized controlled studies and ensuring that an adequate safety pro-
file is achieved.
THINKING ABOUT EARLY-STAGE DISEASE: Two tumour types
where drug development is moving to investigate early-stage
disease were presented: (1) Non-small cell lung cancer, one of
the leading causes of cancer-related mortality. Even after
adequate surgical resection, the majority of patients develop
recurrence of disease, an estimated two-thirds at distant sites.
The presence of micrometastatic disease at the time of resec-
tion is the likely reason for the recurrence and provides a ratio-
nale for the use of adjuvant chemotherapy for patients with
early-stage disease following surgical resection.2 Currently, neo-
adjuvant chemotherapy3 or chemoradiation4,5 are also being
investigated.
(2) Prostate cancer is typically a disease of men over age 50, but
the incidence is projected to increase by 3.4% annually. Family
history is a significant risk factor, but benign prostate hypertro-
phy is not. The key to thinking about early treatment is that pros-
tate cancer progresses through well-described stages.
Prostatectomy remains the cornerstone of treatment. Prostate-
specific antigen (PSA) is a tumour marker, but the correlation
between PSA response and final clinical benefit is not 100%. When
PSA increases after surgery, androgen ablation is the usual treat-
ment. When the PSA concentration rises again and the tumour
becomes resistant to androgen ablation, chemotherapy is the
usual treatment. Only at late stages does the cancer growth
become androgen-independent. The mechanisms behind the
so-called ‘androgen independence’ are being investigated to iden-
tify targets for preserving responsiveness to anti-androgen ther-
apy and inhibiting invasion and metastatic spread. An agent
that could prevent or delay the ‘escape’ of the tumour from
androgen dependence could be used in combination with
anti-androgen therapy. Interleukin-6 (IL-6) is a secreted, multi-
functional cytokine that is produced by tumour cells and
tumour-associated stroma in response to inflammation, stress
and injury, and is upregulated in many types of cancer.6 In a pro-
spective study of 80 patients with prostate cancer serum levels of
IL-6 (and TNF) correlated directly with the extent of malignant
disease.7 Levels of IL-6 are increased in therapy-resistant prostate
cancer. It is a positive growth factor in late-stage prostate cancer
and its autocrine loop appears to be a factor causing the tumour
to become androgen independent. It may also play a role related
to the inflammation and growth of early-stage disease.
Several exploratory studies across the disease-spectrum of
prostate cancer have been started with CNTO 328, a mouse–
human chimeric anti-IL-6 antibody. These studies offer opportu-
nities for translational research, and should thus increase our
understanding of the IL-6 biology in prostate cancer.
INFLAMMATION AND CANCER: Cancer initiation, promotion,
and progression are normally repressed by redundant intra- and
extracellular control mechanisms. One hypothesis is that dysreg-
ulated inflammatory processes are evident in cancer from an
early stage and that cytokine mediators promote tumour growth
and cancer-related morbidity. Investigators have shown that anti-
inflammatory drugs can inhibit tumour formation and that
chronic inflammation is associated with increased incidence of
malignancy.8
Tumour necrosis factor-a (TNFa) has a long history. Since the
early 20th century, there has been considerable interest in the
effects of bacterial infection or bacterial ‘products’ on malignant
tumours in man. The discovery of TNFa in 1975 by E.A. Carswell9
ended a search for an important component of novel therapy
developed by Willam B. Coley, a New York surgeon and pioneer
in immunotherapy for cancer who 75 years earlier demonstrated
that a crude bacterial filtrate from cultures of Streptococcus pyoge-
nes and Serratia marcescens induced high fever and tumour necro-
sis in patients with sarcomas, carcinomas, and lymphomas.10
Coley achieved a cure rate of better than 10%.11 The composition
of ‘Coley’s toxins’ remained an enigma until 1975, when E.A. Car-
swell demonstrated that endotoxin stimulated the production of
a host-specific factor from macrophages that could cause haem-
orrhagic necrosis of tumours. The same protein, secreted by mac-
rophages, initially found to suppress the expression of enzymes
of lipid metabolism in adipocytes in vitro, induced a cachectic
state in vivo caused by systemic suppression of the enzyme lipo-
protein lipase.12 Subsequently, cachectin was found to be identi-
cal to TNFa.13
The action of macrophages on tumour cells provokes the
release of TNFa, leading to induction of myc, ras, and b-catenin
proto-oncogenes; induction of angiogenesis; and induction of
metalloproteinases involved in tissue remodeling and metastasis.
Down-regulation of cadherins leads to increased cell motility.
Evidence supporting the use of anti-TNF regimens is
mounting in renal and ovarian cancers and haematological
malignancies such as myelodysplastic syndrome. Because of the
pro-inflammatory effects of TNFa in para-neoplastic syndromes,
anti-TNF therapies warrant investigation in supportive care indi-
cations such as cachexia, fatigue, asthenia and depression, as
well as therapy of solid tumours.
This approach has required novel studies designs and ‘out of
the box’ thinking. Thus far, in several studies that included over
300 cancer patients in total, mainly in late stage disease, there
has been no evidence that blocking TNF accelerated malignant
growth or progression. The side effect profile is satisfactory com-
pared to that of cytotoxic drugs. The investigators have seen clin-
ical benefit in terms of fatigue scores, subjective patient reports,
and some evidence of antitumour activity. Possibilities to move
into early stage disease and combination regimens are being
investigated.
CONCLUSION: The recommendation is to (1) performmore stud-
ies to explore the safety and efficacy of cytotoxic drugs and drug
combinations in early stages of cancer; (2) develop molecularly
targeted agents for use in early-stage disease, with an emphasis
on proof-of-concept for novel hypotheses and endpoints; (3)
define biomarkers before moving to phase III; and (4) collaborate
more closely with pre-clinical researchers.
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WHY COMBINE TARGETED AGENTS?: While a number of tar-
geted agents have demonstrated clinical proof of principle as can-
cer therapeutics, the clinical benefits conferred by these targeted
agents are still limited, except in few circumstances where the
tumour pathogenesis is dominated by a single molecular abnor-
mality. Reasons for resistance to or escape from targeted agents
can be multiple, including absence or biological irrelevance of
the intended targets, redundant tumour growth and survival
pathways, or heterogeneity of tumour subclones. Optimization
of the therapeutic strategies should therefore include identifica-
tion of predictive markers for individualized selection of thera-
pies, and combination of targeted agents to simultaneously
block the multiple molecular pathways. Discussions in this ses-
sion were focused on strategies to overcome a host of intellectual
property, regulatory, and scientific challenges in the development
of regimens containing multiple targeted agents.1
INTELLECTUAL PROPERTY CHALLENGES: Combining targeted
agents when they are still investigational presents special chal-
lenges concerning intellectual property (IP), since individual
agents of interest are commonly under development by different
industry sponsors. Broad experience exists at the Cancer Treat-
ment Evaluation Program (CTEP) at the National Cancer Institute
(NCI) in the United States in sponsoring combination studies.
With access to more than a hundred investigational agents
through collaborative agreements with industry partners, CTEP
is uniquely positioned to provide a common platform to facilitate
studies combining two or more investigational agents. To encour-
age sponsors to provide proprietary agents for combination stud-
ies, CTEP has developed common intellectual property language,
which stipulates the option for each collaborator to receive non-
exclusive, royalty-free licenses to the combination IP for all pur-
poses including that of commercial use. (The template language
is available on the CTEP Website at http://CTEP.cancer.gov/indus-
try/ipo.html).
This template language has been well accepted by collabora-
tors and investigators. Under such agreements CTEP has spon-
sored >100 clinical trials and executed >60 preclinical materials
transfer agreements (MTAs) for studying combinations between
investigational agents.
REGULATORY ISSUES: Based on experience as sponsor of clini-
cal studies, preclinical toxicology for a combination regimen is
usually not required if adequate safety information in patients
are available for the individual agents. For approval of two exper-
imental agents in combination, it would probably be necessary to
demonstrate the contribution of each component of a fixed com-
bination regimen. Such evidence could generally be obtained in
clinical studies or form compelling preclinical data on the value
of combination and absence of activity with single agent.
GENERAL CONSIDERATIONS FOR CLINICAL EVALUATION OF
TARGET AGENT COMBINATIONS: Given the number of targeted
agents and almost limitless possibilities of combinations, a strat-
egy of prioritization would clearly be necessary.
Priority can be established based on the rationale of the tar-
gets, the credentials of the agent, and the strength of the preclin-
ical data for the combination. The primary target should be
relevant to the tumour being treated. The second target of the
combination regimen may be selected to (1) maximize inhibition
of the same signal (e.g., targeting both vascular endothelial
growth factor [VEGF] and its receptor), (2) maximize inhibition
of a pathway through inhibition of vertical targets (e.g., HER-2
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